Align Technology, Inc. vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
7.1
Bullish
Overall
6.7
Neutral
Quality
Health
Growth
Valuation
Sentiment
ALGN
Clean balance sheet with low leverage (0.0× debt-to-equity).
MRK
Forward P/E of 11.5× is low relative to sector peers.
Analyst Consensus
BUY
Target $209.00 (+16.8%)
14 analysts
BUY
Target $129.74 (+15.7%)
27 analysts
Fundamentals
ALGN
MRK
30.0×
Trailing P/E
31.5×
14.5×
Forward P/E
11.5×
10.5%
Profit Margin
13.6%
70.5%
Gross Margin
76.6%
10.8%
ROE
—
6.2%
Revenue Growth
4.9%
23.9%
Earnings Growth
—
1.81
Beta
0.28
—
Price / Book
—
$12.8B
Market Cap
$277.0B
$122 – $208
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →